235. 副甲状腺機能低下症 Disease details / Clinical trials / Drug dev / DR info

200-1600 µG OF MBX 2109 ONCE-weekly BY subcutaneous injection
   MBX Biosciences
      2024   Phase 2   NCT06531941   United States
400 µG OF MBX 2109 ONCE-weekly BY subcutaneous injection
   MBX Biosciences
      2024   Phase 2   NCT06531941   United States
Acetate
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina
Alfacalcidol
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France
Allogenic parathyroid cells
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05186883   -
AMOR-1
   Amorphical Ltd.
      2024   Phase 2   NCT06547151   Israel
Amorphous calcium carbonate
   Amorphical Ltd.
      2013   -   NCT06288490   Israel
      2013   Phase 1/Phase 2   NCT01815021   Israel
Autofluorescent detection + injection OF indocyanine green
   Onze Lieve Vrouw Hospital
      2021   Phase 3   NCT05117853   Belgium
AZP-3601
   Amolyt Pharma
      2020   Phase 1   NCT05239221   Hungary;Netherlands
Betamethasone
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina
Blood sample
   Hospices Civils de Lyon
      2021   -   NCT04671719   France
Calcitriol
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China
Calcitriol & calcium
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1991   Phase 2   NCT00001304   United States
Calcium
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China
   West China Hospital, Sichuan University
      2019   -   ChiCTR1900022194   China
Calcium carbonate
   Campus Bio-Medico University
      2019   Phase 4   NCT03425747   Italy
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan
Calcium carbonate and alphacalcidol
   University of Athens
      2017   -   NCT04146259   Greece
Calcium citrate
   Campus Bio-Medico University
      2019   Phase 4   NCT03425747   Italy
Calcium gluconate
   National Center for Research Resources (NCRR)
      1995   -   NCT00004361   -
Calcium lactate
   kawasaki medicak school
      2009   Phase 3   JPRN-UMIN000002155   Japan
Carbon
   The Sixth Medical Center of PLA General Hospital
      2020   Phase 0   ChiCTR2300077263   China
CLTX-305
   National Institute of Dental and Craniofacial Research (NIDCR)
      2020   Phase 2   NCT04465227   United States
Crystalline calcium carbonate
   Amorphical Ltd.
      2024   Phase 2   NCT06547151   Israel
Crystalline calcium supplements
   Amorphical Ltd.
      2013   Phase 1/Phase 2   NCT01815021   Israel
Dexamethasone
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
EBP05
   Entera Bio Ltd.
      2023   Phase 1/Phase 2   NCT05965167   Israel
      2018   Phase 2   NCT03516773   Israel
EBP11
   Entera Bio Ltd.
      2023   Phase 1/Phase 2   NCT05965167   Israel
EBP22
   Entera Bio Ltd.
      2023   Phase 1/Phase 2   NCT05965167   Israel
Empiric USE OF calcium carbonate and calcitriol
   CHU de Quebec-Universite Laval
      2017   -   NCT03249012   Canada
Encaleret
   National Institute of Dental and Craniofacial Research (NIDCR)
      2023   Phase 2   NCT05735015   United States
Eneboparatide
   Amolyt Pharma
      2023   Phase 3   NCT05778071   Canada;Denmark;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Portugal;Spain;United Kingdom;United States
Esidrex-R 25 MG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
Ether
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Forsteo
   Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
      2014   Phase 3   EUCTR2013-001890-26-IT   Italy
Forsteo-R
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
Forteo 20 MG
   Entera Bio Ltd.
      2023   Phase 1/Phase 2   NCT05965167   Israel
Human recombinant parathyroid hormone
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NO   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-ES   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Hydrochlorothiazide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
ICG
   University Hospital, Brest
      2021   Phase 3   NCT04785443   France
Immediate post operative bioassay OF parathyroid hormone
   Centre Hospitalier Universitaire de Nimes
      2012   -   NCT02924532   -
Indocyanine green
   Hospital Son Espases
      2016   Phase 4   NCT04012476   Spain
   Hospital Universitari Son Espases
      2020   Phase 4   EUCTR2019-003506-26-ES   Spain
   IRCCS San Raffaele
      2022   -   NCT05328076   Italy
Indocyanine green near infrared fluorescence imaging
   University Medical Center Groningen
      2020   Early Phase 1   NCT06579430   Netherlands
Infracyanine
   CHRU de Brest
      2021   Phase 3   EUCTR2020-005189-32-FR   France
INN parathyroid hormone (1-84) human
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom
Magnesium
   University of Tartu
      2009   -   NCT00824226   Estonia
MBX 2109
   MBX Biosciences
      2024   Phase 2   NCT06465108   Argentina;United States
Methylene blue
   The Sixth Medical Center of PLA General Hospital
      2020   Phase 0   ChiCTR2300077263   China
Natpar
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NO   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-ES   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Natpara/natpar
   Entera Bio Ltd.
      2018   Phase 2   NCT03516773   Israel
NEAR-infrared-induced autofluorescence and indocyanine green NEAR-infrared angiography
   Odense University Hospital
      2021   -   NCT05130476   Denmark
Npsp 558
   NPS PHARMACEUTICALS
      2009   -   EUCTR2008-005063-34-IT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom
      2011   -   EUCTR2011-001265-40-HU   Hungary
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
NPSP558
   Shire
      2011   Phase 3   NCT01455181   Hungary
      2011   Phase 3   NCT01297309   United States
      2011   Phase 3   NCT01268098   United States
      2008   Phase 3   NCT00732615   Belgium;Canada;Denmark;France;Hungary;Italy;United Kingdom;United States
Ormone paratiroideo DA DNA ricombinante
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-IT   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
Oxygen
   Chongqing People's Hospital
      2023   -   ChiCTR2300076192   China
Palopegteriparatide
   Ascendis Pharma Bone Diseases A/S
      2022   -   NCT05654701   -
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Parathyroid allotransplant
   Peter Stock
      2025   Phase 1/Phase 2   NCT06961071   United States
Parathyroid hormon 1-84
   University of Bergen
      2016   Early Phase 1   NCT02986607   Norway
Parathyroid hormone
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark
   Entera Bio Ltd.
      2014   Phase 2   NCT02152228   Israel
   NPS Pharmaceuticals, Inc.
      2011   -   EUCTR2011-001265-40-HU   Hungary
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
   Takeda Pharmaceutical Company Limited
      2022   Phase 3   JPRN-jRCT2080224751   Japan
Parathyroid hormone (1-84) human recombinant
   NPS Pharmaceuticals, Inc.
      2015   Phase 1   EUCTR2015-003108-22-GB   United Kingdom
Parathyroideahormon
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark
PCO371
   Chugai Pharmaceutical
      2020   Phase 1   NCT04209179   Canada;Hungary;United States
Phosphate
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-DI
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Poly(OXY-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbon
   Ascendis Pharma Bone Diseases A/S
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Postoperative laboratory blood tests AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative laboratory blood tests AT 6 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative laboratory drainage fluid tests AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative nausea and vomiting AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative nausea and vomiting AT 6 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative pain AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative pain AT 6 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative sore throat and hoarseness AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Postoperative sore throat and hoarseness AT 6 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Potassium sparing diuretic
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France
Preoparative blood laboratory tests
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Preotact
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark
   NPS Pharmaceuticals, Inc.
      2011   -   EUCTR2011-001265-40-HU   Hungary
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
PTH
   Columbia University
      2009   Phase 3   NCT01199614   United States
   John P. Bilezikian
      2004   Phase 2/Phase 3   NCT00473265   United States
   Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
      2021   Phase 1-2   ChiCTR2100041719   China
   University of Aarhus
      2008   Phase 2   NCT00730210   Denmark
   kawasaki medicak school
      2009   Phase 3   JPRN-UMIN000002155   Japan
PTH 1-34
   National Institute of Dental and Craniofacial Research (NIDCR)
      2006   Phase 3   NCT00395538   Austria;Italy;United States
PTH based calcium carbonate and calcitriol repletion
   CHU de Quebec-Universite Laval
      2017   -   NCT03249012   Canada
PTH1-84 IN parent study
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2010   Phase 3   NCT00856401   United States
Rhpth
   NPS Pharmaceuticals, Inc.
      2011   -   EUCTR2011-001265-40-HU   Hungary
      2010   -   EUCTR2008-005063-34-LT   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2010   -   EUCTR2008-005063-34-HU   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-GB   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   Phase 3   EUCTR2008-005063-34-FR   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2009   -   EUCTR2008-005063-34-DK   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
      2008   Phase 3   EUCTR2008-005063-34-BE   Belgium;Denmark;France;Hungary;Italy;Lithuania;United Kingdom
   Shire
      2022   Phase 3   NCT03878953   Japan
      2018   Phase 3   NCT03364738   Canada;Denmark;Hungary;United States
      2018   Phase 4   NCT03324880   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2017   Phase 1   NCT03150108   United States
      2017   Phase 1   NCT02781844   Canada;Denmark;Hungary;United States
      2016   Phase 4   NCT02910466   United States
   Shire Human Genetic Therapies, Inc.
      2018   Phase 3   EUCTR2017-003067-36-HU   Canada;Denmark;Hungary;United States
      2018   Phase 3   EUCTR2017-003067-36-DK   Canada;Denmark;Hungary;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-SE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-PT   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NO   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-ES   Belgium;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-DK   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-000284-32-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Portugal;Spain;Sweden;United Kingdom;United States
   Takeda Pharmaceutical Company Limited
      2022   Phase 3   JPRN-jRCT2080224751   Japan
Saline 0.9% nacl
   Hospital Italiano de Buenos Aires
      2016   Phase 4   NCT02652884   Argentina
Serum calcium concentrations results
   Hospices Civils de Lyon
      2019   -   NCT04126941   France
Sevelamer
   Hokusetsu ROD Study Group
      2006   -   JPRN-UMIN000000475   Japan
Sodium citrate
   National Center for Research Resources (NCRR)
      1995   -   NCT00004361   -
Standard treatment according TO THE clinical protocols
   Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
      2022   Phase 1/Phase 2   NCT05186883   -
SUB21634
   Aarhus University Hospital, Dept of Endocrinology and Metabolism C
      2008   Phase 4   EUCTR2008-000606-36-DK   Denmark
Symptomatic hypocalcaemia AT 24 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Symptomatic hypocalcaemia AT 6 hour
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Synthetic human parathyroid hormone 1-34
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      2008   Phase 2   NCT00743782   United States
      1991   Phase 2   NCT00001304   United States
Teriparatide
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France
   Dipartimento di Medicina e Chirurgia Traslazionale dell’Università degli Studi di Firenze
      2014   Phase 3   EUCTR2013-001890-26-IT   Italy
   Mayo Clinic
      2010   Phase 2   NCT01171690   United States
   Saint Petersburg State University, Russia
      2021   Phase 3   NCT04750460   Russian Federation
   The Seventh Medical Center, PLA General Hospital
      2021   -   ChiCTR2100047758   China
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleava
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
Teriparatide conjugated TO A multiarm polyethylene glycol carrier molecule through A cleavable linker
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
   Ascendis Pharma Bone Diseases A/S
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Thiazide
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 2   NCT02824718   France
Thymus/parathyroid transplantation
   M. Louise Markert
      2005   Phase 1   NCT00566488   United States
Total thyroidectomy
   Medical University of Lodz
      2020   Phase 4   NCT04412694   Poland
Transcon PTH
   Ascendis Pharma Bone Diseases A/S
      2022   -   NCT05654701   -
      2021   Phase 3   EUCTR2020-003380-26-HU   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-FR   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DK   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2021   Phase 3   EUCTR2020-003380-26-DE   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2020   Phase 3   EUCTR2020-003380-26-NO   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
   Visen Pharmaceuticals (Shanghai) Co., Ltd.
      2021   Phase 3   NCT05387070   China
Transcon PTH HIGH-dose PEN
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
   Ascendis Pharma Bone Diseases A/S
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH LOW-dose PEN
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
   Ascendis Pharma Bone Diseases A/S
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Transcon PTH MID-dose PEN
   Ascendis Pharma Bone Disease A/S
      2021   Phase 3   EUCTR2020-003380-26-IT   Canada;Denmark;France;Germany;Hungary;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-IT   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
   Ascendis Pharma Bone Diseases A/S
      2019   Phase 2   EUCTR2018-004815-33-NO   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-GB   Canada;Denmark;Germany;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DK   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
      2019   Phase 2   EUCTR2018-004815-33-DE   Canada;Denmark;Germany;Italy;Norway;United Kingdom;United States
Tériparatide
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
UN-alpha-R 0.25µG
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 2   EUCTR2016-000500-29-FR   France
Vitamin D
   University of Wisconsin, Madison
      2005   Phase 4   NCT00581828   United States
   West China Hospital, Sichuan University
      2019   -   ChiCTR1900022194   China